Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Jun 04, 2014 3:22pm
166 Views
Post# 22630500

RE:RE:Third Party ASSURE

RE:RE:Third Party ASSUREHi GV. Thanks for being able to get this.

It's disappointing that it is like pulling teeth to get any information from RVX. They really need a communications strategy and expert in place. Also, seems like they have that sort of passive, no hustle attitude in place. High salaries, in spite of very limited performance certainly reduces the sense of urgency in any company. It's better to keep management hungry so they need to pull up their socks and get moving. 

RVX and Zenith seem to have very promising science but they are at the stage where the heat should be put on management. There are lots of great leaders out there that could take on the CEO job and get things moving.

Of course, as always, I'd love to have egg on my face when they make an announcement in the next week.

That being said, the response does suggest things are moving ahead toward a trial.

I have retained my position.
Cheers
Toinv


Bullboard Posts